Home
   Links
   Faculty Information
   Activities & Events
   Melanoma Care Centers
 
   Slide Library
   Polling Results
   Patient Resources
 
   Contact Us
   Register
   Log-in
   
 
 
 
 
 
 
 
 
 
Log In

Activity:

Melanoma Brain Metastases

CME Course Duration:

Start Date: 01-28-2010
End Date: 01-27-2011

Speaker:
Mark R. Middleton, PhD, FRCP
Professor Experimental Cancer Medicine and
Consultant Medical Oncologist
University of Oxford Department of Medical Oncology
Churchill Hospital
Oxford, UK



Featured Topic Information:
Please click here to view a webcast (registration required)
Please click here to view the slide library (registration required)
Please click here to listen to the audio (registration required)
Please click here to take the post test and evaluation (registration required)
Please click here if you have any comments or questions relating to this topic

Target Audience

This activity is directed toward surgical oncologists, general surgeons, oncology nurses, medical oncologists, dermatologists, and other healthcare professionals who screen for and/or treat melanoma.

Educational Objective

Faculty Disclosure Statement

Dr. Mark R. Middleton, has disclosed he serves as a consultant to Astrazeneca, and Bristol Myers Squibb, and that he receives grant/research support from Astrazeneca.

This CME program represents the views and opinions of the individual faculty for each case and does not constitute the opinion or endorsement of the editors, the advisory board, the publishing staff, Paradigm Medical Communications, the UPMC Center for Continuing Education in the Health Sciences, UPMC/University of Pittsburgh Medical Center or affiliates, or University of Pittsburgh School of Medicine.

Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including without limitation, FDA-approved uses, and any off-label uses.